Elemental Iron /day

PreclinicalSmall molecule

IIstanbul University - Cerrahpasa

Elemental Iron /day is one of 43 small molecule programs targeting Anemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

AnemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

2 2

Soliris

AstraZeneca

Phase 3

1 3

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

9 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 5

Vafseo

AAkebia Therapeutics

Phase 3

4 6

Omontys

Takeda

Phase 3

9 7

Campath

GGenzyme, a Sanofi Company

Phase 3

2 8

Alkeran

AApotex Inc.

Phase 3

1 9

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

2 10

Sodium Nitroprusside

WWatson Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia1 trial

Risk of Anemia and Effects of Oral Iron Therapy in Non-Anemic Iron-Deficient Women (18-55 Years)

Recruiting·IIstanbul University - Cerrahpasa·N/A·NCT07263529·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Elemental Iron /day. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elemental Iron /day compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elemental Iron /day. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istanbul University - Cerrahpasa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIstanbul University - Cerrahpasa

Elemental Iron /day

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia1 trial

References

Drug Info

Quick Facts

Related News